Biosimilars in Canada and Europe AIPLA Biotechnology Committee Webinar Noel Courage September 25, 2012.

Slides:

Advertisements

Similar presentations

The Drug Discovery Process

Advertisements

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

Center for Clinical Research - Clinical Trials Center (CTC) Clinical Research and Clinical Trials in Switzerland Jürg Lustenberger, PhD Dipl. Pharm. Med.

Biosimilars in Canada: A Perspective from Innovative Industry

FDA Counsel.com 1 ANDAs, OTCs, Orphans and Cosmetics -- Key Issues Wednesday, August 18, 2004 SDRAN RAC STUDY COURSE Michael A. Swit, Esq. FDACounsel.com.

The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.

© Bird & Bird LLP 2010 Thanks to our Sponsors!! Bird & Bird LLP Engel & Novitt, LLP Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.

UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.

Have FDA Expedited Programs Shortened Drug Development Timelines? An analysis of newly approved therapies and how FDA expedited programs impacted drug.

Physician Perspectives on Subsequent Entry Biologics (SEBs) Michael S. Reilly, Esq. Executive Director, Alliance for Safe Biologic Medicines March 31,

Special Topics in IND Regulation

Bureau of Gastroenterology, Infection

1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Health Products and Food Branch Visión Global de la Regulación de Productos Biológicos y Biotecnológicos Dr. Elwyn Griffiths Health Canada, Ottawa Buenos.

Costa Rica Pharma and Biotech Patent Update AIPLA Spring Meeting Seattle, Washington May 2013 Costa Rica Luis Diego Castro Castro.

Assessing Global Standards for Biologic Medicines Richard Dolinar, MD Endocrinologist Chairman of the Alliance for Safe Biologic Medicines Presented at.

Introduction to Biosimilars Biologicals Marketing Authorization Directorate Central Administration for Pharmaceutical Affairs

Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.

The role of biosimilars in BMT Dr Bronwen Shaw Chief Medical Officer, Anthony Nolan Consultant in haematopoietic cell transplantation, Royal Marsden.

Comparison of US/EU Biosimilar Guidelines

Helping the people of Canada maintain and improve their health Aider les Canadiens et les Canadiennes à maintenir et à améliorer leur santé Health Canada’s.

Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Biosimilars – So where are we in the EU? Robert Williams, Partner, Bird & Bird LLP (London)

Clinical trials for regulatory approval of biosimilars

Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

Anthony C. Tridico, Ph.D. AIPLA BIOTECHNOLOGY COMMITTEE Pinning Down a Moving Target: Patenting Biotech in Uncertain Times.

Follow-on or Biosimilar Biologic s Points to Consider Paul Kim Foley Hoag LLP Massachusetts Biotechnology Council Thursday, May 28, 2009 © 2008 Foley Hoag.

Follow-On Biologics: The New Regulatory Frontier [?] Michael S. Labson August 23, 2007.

FDA’s Biosimilars Guidance -- Legal and Regulatory Considerations James S. Cohen, Esq. McDermott Will & Emery DIA Webinar April 10, 2012.

Topics discussed in the presentation

ACCESS TO MEDICINES - POLICY AND ISSUES

Marcel H.N. Hoefnagel 2 November 2007 BIOSIMILARS are not Generics But similar.

Biosimilars Where Are We Now? Where Are We Going? Sheldon Bradshaw January 24, 2008.

Our PatientsOur PeopleOur BusinessOur Community © 2008 Endo Pharmaceuticals. All Rights Reserved. Biosimilars 2009 Update Pending Legislation Review Pam.

'Hot topics' ESSENTIAL MEDICINES FOR CHILDREN Suzanne Hill September 2006.

GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.

Initiatives Drive Pediatric Drug Development January 30, 2002.

Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.

Copyright 2010, Morgan, Lewis & Bockius LLP Healthcare Reform--New Path for Biosimilars Kathleen M. Sanzo, Esq. Washington, DC May.

WHAT IS A BIOSIMILAR? Philip D. Home, DM, DPhil Professor of Diabetes Medicine Newcastle University Consultant Diabetologist Newcastle Diabetes Centre.

Lessons Learned from Standard of Care, First Generation and Next Generation Biotherapeutics: What Do We Expect to Change Going Forward ? Steven J Swanson,

Regulation of Generic Animal Drugs in the United States

Final Canadian Guidelines for “Biosimilars” Subsequent Entry Biologics (SEBs) DIA RA SIAC RD/RI Working Groups 11-May-2010 Stephen Sherman.

SAFETY CONCERNS OF BIOSIMILARS IN TURKEY Serra Vildan Akgül¹, Sevcan Gül Akgün¹, Gülden Z. Omurtag¹, Semra Şardaş¹ ¹ Department of Pharmaceutical Toxicology,

© Coherent market Insights. All Rights Reserved BIOSIMILAR PIPELINE ANALYSIS MARKET Global Industry Insights, Trends, Outlook, and Opportunity Analysis,

NRC’s 10 CFR Part 37 Program Review of Radioactive Source Security

Difference to Generics What can they do for us in the future

Regulatory Updates Health Sciences Authority Singapore

Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.

Australian Jurisdictional Update March 2017

Post-Notice of Compliance (NOC) Changes

What are Biopharmaceuticals?

REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.

What are Biopharmaceuticals?

US Prescribers and Biosimilars Naming

Subsequent Entry Biologics: IP Issues

Kimby N. Barton Interim Director Medical Devices Bureau

Introduction to Biosimilars

Applying Biosimilars in Hematologic Cancers

Health Canada’s Collaboration with the NAC – Provincial TM Network

Understanding Biologics

Biosimilars in RA: A Blessing or a Curse?

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

Biosimilars in Hematologic Oncology

The Rising Cost of Healthcare and Potential Impact of Biosimilars

360-Degree Perspectives on Biosimilars in Oncology

Presentation transcript:

Biosimilars in Canada and Europe AIPLA Biotechnology Committee Webinar Noel Courage September 25, 2012

Europe Europe has been a leader in biosimilar guidance and approvals. Guidelines for insulin, G-CSF, EPO, somatropin, LMW heparins, interferon alpha December 2012: monoclonal Ab guidance takes effect

Monclonal Ab guidance 1.clinical and non-clinical issues -demonstrate biosimilarity to reference antibody -if several indications, not required to investigate pharmacokinetic profile in all. More PK studies if distinct therapeutic areas. 2. Immunogenicity -eg: analyze glycosylation patterns, mechanism of action, clinical factors -risk management plan to prevent, measure, and medically treat adverse immune response

Canada Did not need to implement specific legislation to create biosimilar pathway Using existing regulatory structure

Canada – simple and transparent approach New biologics and biosimilars both approved via NDS, eg somatropin No product-specific guidance. Health Canada recommends consulting EP guidance HC committed as of September 2012 to publish reasons for biosimilar approvals

Cdn. News: G-CSF biosimilar Teva filed NDS in Canada Amgen CA patent 1,341,537 expires 2024 (17 yrs from issuance; DNA, protein, process of production) Amgen trying to block Teva’s marketing authorization Teva alleges patent invalid

Linkage Regulations Canada: – Linkage regs - Health Canada Patent Register EP: – No linkage regs

Naming EP: filgrastim US: tbo-filgrastim Canada: likely to follow EP’s lead, as with somatropin

Regulatory Threshold Canada and EP stress importance of comparative clinical trials to demonstrate biosimilarity For more info see: N. Courage & A. Parsons. The Comparability Conundrum: Biosimilars in the United States, Europe and Canada, (2011) 66 Food and Drug Law Journal. Will the US be any different in data requirements?

Exclusivities and Patents US leads EP and Canada on regulatory exclusivities Patent term extension possible in US, EP (SPC), not CA

Thank You! Sponsors: